General MedicationsOPHTHALMICStandard
VERKAZIA
CYCLOSPORINE
Standard Dose
0.1%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview VERKAZIA is listed in Drugs@FDA under application 214965 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CYCLOSPORINE Form and strength EMULSION;OPHTHALMIC - 0.1% Sponsor HARROW EYE Submission history Latest submission status date: 2021-06-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview VERKAZIA is listed in Drugs@FDA under application 214965 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CYCLOSPORINE Form and strength EMULSION;OPHTHALMIC - 0.1% Sponsor HARROW EYE Submission history Latest submission status date: 2021-06-23 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.